• Cyclopamine: A Hedgehog Signal-to-Phenotype Tool

  2026-08-19

  Cyclopamine is a Hedgehog signaling inhibitor that connects Smoothened perturbation with cancer and developmental phenotypes. This guide explains how comparative genital development research can improve assay design, model selection, and interpretation in cancer research.

• Nocodazole Beyond Cell-Cycle Arrest

  2026-08-19

  Nocodazole is more than a mitotic synchronization reagent: it can expose microtubule-dependent steps in intracellular trafficking and host–pathogen entry. This article translates findings from a Drosophila S2-cell infection study into a rigorous framework for assay design, interpretation, and cross-domain research.

• Regorafenib Suppresses Melanoma Through RRM2

  2026-08-18

  A 2024 iScience study identifies RRM2 as a downstream mediator of Regorafenib activity in melanoma and connects its reduction with impaired proliferation, invasion, metastasis, and increased apoptosis. The work further places the ERK/E2F3 pathway upstream of this response, providing a mechanistic framework for cancer biology research while remaining preclinical.

• Nilotinib Assays: Separating Arrest From Death

  2026-08-18

  Nilotinib (AMN-107) is a powerful probe for BCR-ABL signaling, but kinase potency does not automatically equal cancer-cell killing. This guide applies a phenotype-aware assay framework to chronic myeloid leukemia research, KIT-driven models, and more interpretable viability experiments.

• How Ribotoxic Stress Drives UV-Mediated Cell Death

  2026-08-17

  Sinha et al. show that UV-induced apoptosis is governed primarily by ribosome collisions and the ribotoxic stress kinase ZAK, rather than by the DNA damage response alone. Their time-resolved, multi-method analysis defines GCN2 activation and ZAK degradation as feedback mechanisms that tune cellular tolerance versus death after UV exposure.

• Losmapimod: From p38 Biology to Assay Design

  2026-08-17

  Losmapimod (GW856553X) is a selective p38α/p38β MAPK inhibitor with applications in inflammation, vascular, hypertension, and COPD research. This guide translates new activation-loop biology into practical assay decisions while separating established evidence from testable mechanistic hypotheses.

• U0126-EtOH: MEK1/2 Inhibitor Workflows

  2026-08-16

  U0126-EtOH is a selective MEK1/2 inhibitor for resolving ERK-dependent effects in neuronal, leukemia, and inflammatory models. This practical guide connects pathway validation with dosing, controls, endpoint selection, and troubleshooting for reproducible MAPK/ERK experiments.

• Regorafenib (BAY 73-4506) Assay Guide

  2026-08-15

  A scenario-driven laboratory guide to Regorafenib (BAY 73-4506), SKU A8236, for viability, proliferation, migration, invasion, and angiogenesis research. It connects concentration planning, solvent compatibility, mechanistic interpretation, and product-selection criteria to published melanoma findings and documented kinase activity.

• PPT and the ERα-to-LUAD Translation Gap

  2026-08-14

  PPT (Propyl Pyrazole Triol) offers a pharmacological way to isolate ERα activity from ERβ signaling. By connecting its subtype-selective mechanism with the FOXM1–ERα biomarker network reported in female lung adenocarcinoma, this article outlines a disciplined path from receptor perturbation to translational hypothesis testing.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-08-14

  Chen and colleagues show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through ERK1/2 activation and disruption of bile-acid homeostasis. The study connects estrogenic signaling, altered bile-acid transport and synthesis, and ERK phosphorylation inhibition as experimentally separable features of phytoestrogen-associated hepatotoxicity.

• Trametinib (GSK1120212) Research Workflows

  2026-08-13

  Trametinib (GSK1120212) converts MEK–ERK pathway suppression into a practical workflow for genotype-aware proliferation, cell-cycle, and apoptosis studies. This guide also shows how to extend those assays into a carefully controlled, hypothesis-generating investigation of APEX2-dependent TERT expression.

• AGTR1, ARBs, and Immune Checkpoint Blockade

  2026-08-13

  A 2024 Journal for ImmunoTherapy of Cancer study identifies AGTR1 as a therapeutic vulnerability in collagen-rich, immune-excluded armored and cold tumors. Its data connect angiotensin receptor blockade with reduced cancer-associated fibroblast collagen production, tumor immune remodeling, and improved immune checkpoint blockade responses, while highlighting important limits on clinical interpretation.

• 17-AAG: HSP90 Inhibition as an Assay Strategy

  2026-08-12

  17-AAG (Tanespimycin) is more than a cytotoxic HSP90 inhibitor: it is a mechanistic probe for client-protein dependence, apoptosis, and assay interpretation. This guide connects oncology workflows with new lessons from norovirus–NINJ1 research without overstating cross-domain evidence.

• CX-4945 (Silmitasertib): CK2 Research Guide

  2026-08-12

  CX-4945, also called Silmitasertib, is an ATP-competitive CK2 inhibitor with reported biochemical potency of 1 nM. It provides a research tool for studying CK2-regulated Akt signaling, apoptosis, cell-cycle control, tumor growth, and host-factor biology in viral infection.

• JXY Promotes M1 Polarization in Colitis-Associated CRC

  2026-08-11

  The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1 phenotype through TLR4-associated signaling. Its integrated in vivo, cellular, transcriptional, and pharmacological design supports immune remodeling as a potential mechanism of tumor control, while also highlighting limits on translating macrophage polarization directly to human therapy.

15770 records 1/1052 page Next 12345 下5页 Last page